Meta’s Rust-powered linter and type checker for Python pairs blazing speed with advanced and innovative features.

Telehealth provider Hims & Hers Health Inc. announced Thursday the availability of generic semaglutide through its platform, allowing eligible Canadians access to digital prescriptions for the popular ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Some Canadian ...

Two generic versions of Ozempic are set to start arriving in Canadian pharmacies this week, which means patients who use the drug to treat diabetes or for weight loss may have more options for a ...

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx. The platform, which launched in February, is key to his administration's ...

President Trump announced the addition of 600 medicines to his online drugstore as he appeals to Americans concerned about high drug prices and affordability. By Rebecca Robbins President Trump said ...

Over the last several years, Apple has dramatically improved how it handles lithium-ion battery charging in iPhones, iPads, Macs, and Apple Watches. Across multiple system releases, the company moved ...

Using AI chatbots for even just 10 minutes may have a shockingly negative impact on people’s ability to think and problem-solve, according to a new study from researchers at Carnegie Mellon, MIT, ...

Here’s how to invest in custom visuals and turn that content into years of stronger engagement, trust and brand differentiation. Custom visual content builds trust faster by showing real people, ...

The era of cheap, officially approved semaglutide is finally here—in Canada, that is. The country has just become the first in North America and the first G7 nation to license a generic version of the ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...